Bank of Hawaii Has $2.05 Million Holdings in Pfizer Inc. (NYSE:PFE)

Bank of Hawaii grew its position in Pfizer Inc. (NYSE:PFE) by 0.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,769 shares of the biopharmaceutical company’s stock after buying an additional 564 shares during the quarter. Bank of Hawaii’s holdings in Pfizer were worth $2,048,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in PFE. China Universal Asset Management Co. Ltd. acquired a new position in Pfizer during the first quarter valued at $315,000. Mount Yale Investment Advisors LLC increased its holdings in shares of Pfizer by 25.7% in the 1st quarter. Mount Yale Investment Advisors LLC now owns 22,128 shares of the biopharmaceutical company’s stock valued at $614,000 after purchasing an additional 4,525 shares during the period. Waverly Advisors LLC lifted its position in shares of Pfizer by 36.3% in the first quarter. Waverly Advisors LLC now owns 165,821 shares of the biopharmaceutical company’s stock worth $4,602,000 after purchasing an additional 44,118 shares in the last quarter. Kennedy Capital Management LLC acquired a new stake in shares of Pfizer during the first quarter worth approximately $3,992,000. Finally, Industrial Alliance Investment Management Inc. grew its position in Pfizer by 4.1% during the first quarter. Industrial Alliance Investment Management Inc. now owns 19,089 shares of the biopharmaceutical company’s stock valued at $530,000 after purchasing an additional 751 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on PFE shares. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Sanford C. Bernstein assumed coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Citigroup initiated coverage on shares of Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average price target of $32.92.

Pfizer Trading Up 2.1 %

Shares of Pfizer stock opened at $25.65 on Monday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company’s fifty day simple moving average is $28.21 and its 200-day simple moving average is $28.57. The company has a market cap of $145.36 billion, a price-to-earnings ratio of 34.66, a PEG ratio of 0.82 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the previous year, the firm posted ($0.17) EPS. The business’s revenue was up 31.2% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.55%. Pfizer’s dividend payout ratio is currently 227.03%.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.